Opendata, web and dolomites

NATURE-ETN SIGNED

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NATURE-ETN project word cloud

Explore the words cloud of the NATURE-ETN project. It provides you a very rough idea of what is the project "NATURE-ETN" about.

cells    laboratories    culture    dna    grow    leaders    questions    materials    yield    leverage    extend    editing    combined    chemistry    disciplinary    industry    biologists    immunotherapy    chemists    breakthrough    give    disease    biotech    limitations    engineering    combination    disruptive    21st    commercial    tools    training    scientific    regarding    human    acid    excellence    cancer    outstanding    receive    expertise    pioneering    business    15    sequencing    transferable    technologies    crispr    immunotherapies    paradigm    etn    world    mutations    therapies    generation    outcomes    skillset    serious    today    therapeutic    tech    insertions    stage    functioning    nature    smes    workshops    nucleic    manipulation    career    boundaries    base    unrivalled    quality    meet    deep    environment    discoveries    despite    predicted    fellows    therapy    translation    genomics    century    cas9    nas    biomaterials    skills    off    prolonged    basic    na    treatment    medicine    planning    crystallography    epigenetic    cell    undesired    intersectoral    deletions    applicability    originating    gene   

Project "NATURE-ETN" data sheet

The following table provides information about the project.

Coordinator
DUBLIN CITY UNIVERSITY 

Organization address
address: Glasnevin
city: DUBLIN
postcode: 9
website: www.dcu.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 4˙041˙816 €
 EC max contribution 4˙041˙816 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DUBLIN CITY UNIVERSITY IE (DUBLIN) coordinator 824˙052.00
2    THE UNIVERSITY OF READING UK (READING) participant 606˙345.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
4    USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. CZ (PRAHA 6) participant 469˙743.00
5    ATDBIO LIMITED UK (SOUTHAMPTON HAMPSHIRE) participant 303˙172.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
7    ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS FR (PARIS CEDEX 05) participant 274˙802.00
8    NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED IE (BLACKROCK DUBLIN) participant 274˙684.00
9    BASECLICK GMBH DE (NEURIED) participant 252˙788.00
10    UNIWERSYTET WARSZAWSKI PL (WARSZAWA) participant 227˙478.00

Map

 Project objective

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NATURE-ETN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NATURE-ETN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More